Wang JF, Lu HD, Wang Y, Zhang R, Li X, Wang S. Clinical characteristics and prognosis of non-small cell lung cancer patients with liver metastasis: A population-based study. World J Clin Cases 2022; 10(30): 10882-10895 [PMID: 36338221 DOI: 10.12998/wjcc.v10.i30.10882]
Corresponding Author of This Article
Sheng Wang, MD, PhD, Chief Doctor, The First Department of Thoracic Oncology, Jilin Province Tumor Hospital, No. 1018 Huguang Street, Changchun 130021, Jilin Province, China. wangsh2334@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jun-Feng Wang, Hong-Di Lu, Ying Wang, Rui Zhang, Sheng Wang, The First Department of Thoracic Oncology, Jilin Province Tumor Hospital, Changchun 130021, Jilin Province, China
Xiang Li, Big Data Center for Clinical Research, Jilin Province Tumor Hospital, Changchun 130021, Jilin Province, China
Author contributions: Wang JF and Wang S designed the study; Wang JF and Lu HD wrote the manuscript; Wang Y and Zheng R contributed to the data collection; Wang JF, Li X, and Wang S performed the statistical analysis; Li X revised the manuscript; all authors read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of the Jilin Province Tumor Hospital.
Conflict-of-interest statement: We have no financial relationships to disclose for this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sheng Wang, MD, PhD, Chief Doctor, The First Department of Thoracic Oncology, Jilin Province Tumor Hospital, No. 1018 Huguang Street, Changchun 130021, Jilin Province, China. wangsh2334@163.com
Received: June 19, 2022 Peer-review started: June 19, 2022 First decision: July 13, 2022 Revised: July 24, 2022 Accepted: September 16, 2022 Article in press: September 16, 2022 Published online: October 26, 2022 Processing time: 123 Days and 12 Hours
Core Tip
Core Tip: Metastatic disease to distant organs from non-small cell lung cancer (NSCLC) is the main reason for poor survival. The liver is one of the most commonly involved extra-pulmonary sites of metastasis in NSCLC patients. The presence of liver metastasis (LM) is an independent prognostic factor for shorter survival in NSCLC patients. The median overall survival of patients with involvement of the liver is less than 5 mo. At present, identifying prognostic factors and constructing survival prediction nomogram for NSCLC patients with LM (NSCLC-LM) are highly desirable. We aimed to identify independent predictors and further build a novel risk stratification system to predict cancer-specific survival (CSS) of NSCLC-LM patients. To the best of our knowledge, our study was the first Surveillance, Epidemiology, and End Results (SEER)-based study to determine prognostic factors affecting CSS in NSCLC patients with liver involvement.
